Vaxcyte enters manufacturing pact with Lonza for pneumococcal vaccine

Vaxcyte, Inc.

Master Services Agreement effective March 22, 2022 for clinical manufacturing of Vaxcyte's PCV.
Initial term of five years; either party may terminate for material breach, insolvency, or convenience.
Vaxcyte owns IP directly derivative of its product; Lonza owns generally applicable IP or improvements to Lonza background.
No financial terms disclosed; Lonza paid for services, pass-through costs, and a procurement fee.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.